Vanda Pharmaceuticals Inc.
Close on Oct 19, 2026
- Market cap
- $246.33M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | $51.70M | $-0.82 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 11, 2026 | After market close | $57.20M | $-2.39 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | After market close | $56.26M | $-0.38 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | Before market open | $52.60M | $-0.46 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | $50.04M | $-0.50 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 13, 2025 | After market close | $53.20M | $-0.08 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $47.70M | $-0.09 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 7, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on May 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Total revenues | Full Year 2026 | $240.00M to $290.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Vanda Pharmaceuticals filed with the SEC
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
Other events · EX-99.1 to Form 8-K
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
Other events · EX-99.1 to Form 8-K
FDA Declines to Approve Vandas Marketing Application for Tradipitant in Gastroparesis
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Confirms Receipt of Unsolicited,
Regulation FD disclosure · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
Material agreement · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
(iloperidone) Receives U.S. FDA Approval
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ ® ANDA
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Provides an Update to HETLIOZ ® ANDA
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ ® ANDA
Other events · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K